New First-in-Human Study Presented at ISSCR 2026 Explores Immune-Engineered Cell Therapy Approach for Type 1 Diabetes

Research evaluates whether hypoimmune cell engineering can help transplanted insulin-producing cells survive without chronic immunosuppression New research presented today at the International Society for Stem Cell Research (ISSCR) 2026 Annual Meeting explores an approach that could expand the potential of cell replacement therapy for type 1 diabetes by evaluating whether immune-engineered,…